Articles On Immutep (ASX:IMM)

ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios   The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point...

Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab).

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c...

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September....

Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent...

Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board.

Immutep (IMM) signs a material transfer agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, PolandThe partnership will enable an investigator-initiated open label Phase II clinical trial to evaluate...

Uscom’s device is included in China’s emergency guidelines Poland provides grant for Immutep’s Phase 2 trial Medical device company Uscom (ASX:UCM) said that it has been included in the national emergency medicine guidelines for acute hea...

ShareCafeEvening Report: 30 August, 2022 by Paul Sanger   Australian shares have clawed back some of yesterday’s heavy losses despite another slump in global markets over the possibility of more aggressive US and European interest rate hike...

Immutep (IMM) receives a new patent for its immunotherapy treatment for cancer from the Japanese Patent Office The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead acti...

ShareCafeLunch Report: 30 August, 2022 by Paul Sanger   The ASX had a solid start to the trading session Tuesday, recovering some of yesterday’s material fall. At noon, the S&P/ASX 200 is 0.48 per cent or 33.50 points higher at 6999.00....

ShareCafeStocks of the Hour: 30 August, 2022                    Cobre (ASX:CBE) continues to kick goals, today they announced that their fifth step out drill hole of the ongoing diamond drill programme at the Ngami Copper Project in t...

30 Aug 2022 - A snapshot of the stocks on the move featuring Cobre (ASX:CBE), Immutep (ASX:IMM) and AD1 Holdings (ASX:AD1).

It is the last day of the busiest week in the August earnings season. Thankfully, you can ease into the weekend with far fewer ASX shares set to report their results today. However, there are still a handful of big names that you might wa...

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials. The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod...

Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased. However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen i...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market. Here’s a closer look at three noteworthy ASX biotech shares and their outlook for FY23. CSL Ltd...

The Immutep Ltd (ASX: IMM) share price plunged lower in June despite the company announcing seemingly good news to the market. As of the final close of last month, the Immutep share price was 29 cents, 30.95% lower than it was at the end o...

ASX healthcare shares were a mixed basket this past financial year. After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January. The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

Immutep (IMM) is granted a Japanese patent for its pre-clinical product candidate, IMP761, valid until 2036 The patent is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office The new patent follows the grant of th...

06 Jul 2022 - Immutep (ASX:IMM) has been granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.

ASX 200 healthcare shares were defensive in June but finished the month down overall. The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let’...

Shares of biotech Immutep Ltd (ASX: IMM) have had a hard time this year to date, down 35% since trading resumed in January. At the time of writing, investors are paying 30.5 cents apiece for the Immutep share price. Earlier this month,...

Exchange-traded funds (ETFs) can be very useful for investing in shares. ETFs make it to invest passively, get access to different industries or invest in different geographic markets. One of the most popular ETFs is one that gives access...

The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents. Investors pushed the stock to 52-week lows by April this year, wh...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. After rallying from t...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. With the recent infla...

Men are more likely to invest in ASX shares than women. That’s according to a new YouGov survey commissioned by crypto wealth platform Dacxi. The survey also found that men are almost twice as likely to believe they’ll be rich in their...

ShareCafeImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022   Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christia...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

In Short & Caught, Stockhead recaps the ASX stocks that are the most shorted and have had the greatest increase in short interest right now.   How does shorting work? Shorting works by selling stocks you do not actually own in the hope...

Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

ShareCafeEvening Report: 6 June, 2022 by Lauren Evans   The Aussie sharemarket remained in the red for the afternoon session following a weak lead from Wall Street. The Reserve Bank of Australia is set to meet tomorrow, which means investor...

ShareCafeLunch Report: 6 June, 2022 by Melissa Darmawan   The Australian sharemarket has retreated this morning after three weeks of gains ahead of the Reserve Bank of Australia policy meeting tomorrow. Energy is the clear winner while cons...

US FDA approves Clarity Pharma’s IND application Radiopharma-focused biotech, Clarity Pharmaceuticals (ASX: CU6), has announced the approval of its Investigational New Drug (IND) application by the US FDA. The approval was received for Clar...

06 Jun 2022 - A snapshot of the stocks on the move featuring Immutep (ASX:IMM), Liontown Resources (ASX:LTR) & Calidus Resources (ASX:CAI).

Immutep (IMM) publishes new “favourable” data from its first line non-small cell lung cancer (NSCLC) patients of its Phase II TACTI-002 trial The trial is evaluating eftilagimod alpha (efti) when used with collaboration partner MSD’s anti-...

ASX healthcare index finishes another week in the red Enterprise imaging stocks tipped to be a first recovery The goliath battle for fertility company Virtus comes to an end Healthcare and life sciences expert Scott Power – a senior analy...

May. Let’s start with US markets. Because May in the US started with the Dow making its biggest gain since 2020, followed within 24 hours by its biggest loss in 2022, perfectly summing up what kind of month May was to become. The US Fed rai...

The last 30 days have been bright for the Immutep Ltd (ASX: IMM) share price. The biotechnology company’s surge followed two announcements regarding its lead product candidate, efti. At the time of writing, the Immutep share price is 41 ce...

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Immutep (IMM) publishes new interim data from Part A of its second-phase TACTI-002 trial showing “favourable” antitumour activity for its eftilagimod alpha (efti) drug. Data from the trial will be presented in an oral presentation on June...

 ASX to open 1% higher this morning Wall Street surge in a broad based rally overnight April retail sales data to be released today Local shares are poised to open higher this morning following a jump in US stocks overnight. At 8am AEDT,...